KR20180063125A - 악성종양을 치료하기 위한 복합 요법 - Google Patents

악성종양을 치료하기 위한 복합 요법 Download PDF

Info

Publication number
KR20180063125A
KR20180063125A KR1020187010260A KR20187010260A KR20180063125A KR 20180063125 A KR20180063125 A KR 20180063125A KR 1020187010260 A KR1020187010260 A KR 1020187010260A KR 20187010260 A KR20187010260 A KR 20187010260A KR 20180063125 A KR20180063125 A KR 20180063125A
Authority
KR
South Korea
Prior art keywords
dose
compound
day
cytarabine
aml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187010260A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 브이. 아그레스타
Original Assignee
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지오스 파마슈티컬스 아이엔씨. filed Critical 아지오스 파마슈티컬스 아이엔씨.
Priority to KR1020257014978A priority Critical patent/KR20250065944A/ko
Publication of KR20180063125A publication Critical patent/KR20180063125A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187010260A 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법 Ceased KR20180063125A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014978A KR20250065944A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US62/242,256 2015-10-15
US201562255194P 2015-11-13 2015-11-13
US62/255,194 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014978A Division KR20250065944A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Publications (1)

Publication Number Publication Date
KR20180063125A true KR20180063125A (ko) 2018-06-11

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257014978A Pending KR20250065944A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법
KR1020187010260A Ceased KR20180063125A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020257014978A Pending KR20250065944A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Country Status (15)

Country Link
US (2) US10905692B2 (enExample)
EP (2) EP3362057A1 (enExample)
JP (2) JP2018534288A (enExample)
KR (2) KR20250065944A (enExample)
CN (1) CN108366980A (enExample)
AU (1) AU2016340087C1 (enExample)
BR (1) BR112018007304A2 (enExample)
CA (1) CA3001599A1 (enExample)
CL (1) CL2018000927A1 (enExample)
EA (1) EA201890968A1 (enExample)
IL (2) IL311873A (enExample)
MX (2) MX394796B (enExample)
SG (1) SG10201912886XA (enExample)
WO (1) WO2017066599A1 (enExample)
ZA (1) ZA201802088B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EP3362070B1 (en) 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Celgene Corporation composições de comprimido
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
CN115243690A (zh) 2019-11-14 2022-10-25 新基公司 用于治疗癌症的儿科制剂
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
EP3019490B1 (en) 2013-07-11 2020-06-03 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
EA030428B1 (ru) 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
EP3362070B1 (en) 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
EP3383400B1 (en) 2015-12-04 2022-01-05 Les Laboratoires Servier Methods of treatment of malignancies
MX390396B (es) 2016-02-26 2025-03-20 Celgene Corp Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria.

Also Published As

Publication number Publication date
IL258269A (en) 2018-05-31
IL311873A (en) 2024-06-01
US20180311249A1 (en) 2018-11-01
AU2016340087C1 (en) 2022-08-18
NZ740792A (en) 2024-05-31
KR20250065944A (ko) 2025-05-13
US10905692B2 (en) 2021-02-02
BR112018007304A2 (pt) 2018-10-23
WO2017066599A1 (en) 2017-04-20
SG10201912886XA (en) 2020-02-27
JP2021130682A (ja) 2021-09-09
AU2016340087B2 (en) 2022-05-12
AU2016340087A1 (en) 2018-04-12
MX394796B (es) 2025-03-24
MX2022006701A (es) 2022-07-12
MX2018004595A (es) 2019-07-04
EP3362057A1 (en) 2018-08-22
CL2018000927A1 (es) 2018-09-14
CN108366980A (zh) 2018-08-03
EA201890968A1 (ru) 2018-09-28
EP4147692A1 (en) 2023-03-15
US20210386749A1 (en) 2021-12-16
CA3001599A1 (en) 2017-04-20
JP2018534288A (ja) 2018-11-22
ZA201802088B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
US20210386749A1 (en) Combination therapy for treating malignancies
JP6930991B2 (ja) 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
EP3383400B1 (en) Methods of treatment of malignancies
US20210100805A1 (en) Combination therapy for treating malignancies
US20210113574A1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法
HK40114599A (en) Combination therapy for treating malignancies
EA046110B1 (ru) Способы лечения хронического лимфоцитарного лейкоза с применением 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
EA039805B1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180411

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211012

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220927

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240102

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20241206

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20241206

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250507